医药代表-湛江

浙江博锐生物制药股份有限公司

1000 - 1000 nhân viên

Chinese innovative biopharmaceutical company founded on 23 January 2019 and headquartered in Jiaojiang district, Taizhou, Zhejiang with 633.93 million yuan of registered capital, spun out of Hisun Pharmaceutical's biologics business. Covers research, manufacturing and commercialisation in-house and concentrates on immunology, building autoimmune coverage across collaborating clinical departments and immuno-oncology coverage by cell type. Runs large-scale biologics capacity and a quality system with more than twenty main pipeline products, over ten in the clinic and four commercialised, and employs more than 1,000 people across Taizhou, Hangzhou, Shanghai and San Diego. Entered the Hurun Global Unicorn Index in December 2024 at a 13.5 billion yuan valuation as Taizhou's first certified unicorn.